There are few validated in vivo models of ER+ breast cancer and thus cell line models have played a vital role in studies that have elucidated the molecular mechanisms that determine ER pharmacology and how pathways are dysregulated upon drug resistance. This evidence concerns the gene ESR1 and breast cancer.